{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T10:19:07Z","timestamp":1783937947457,"version":"3.55.0"},"reference-count":43,"publisher":"Informa UK Limited","issue":"6","license":[{"start":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T00:00:00Z","timestamp":1782086400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/doi.org\/10.1080\/policies-text-data-mining"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Review of Pharmacoeconomics & Outcomes Research"],"published-print":{"date-parts":[[2026,7,3]]},"DOI":"10.1080\/14737167.2026.2691183","type":"journal-article","created":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T08:21:00Z","timestamp":1781684460000},"page":"803-811","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":0,"title":["Budget impact analysis of capivasertib as a second-line therapy for advanced breast cancer in the United States"],"prefix":"10.1080","volume":"26","author":[{"given":"Trang","family":"Nguyen","sequence":"first","affiliation":[{"name":"University of Manitoba","place":["Winnipeg, Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shweta","family":"Mital","sequence":"additional","affiliation":[{"name":"University of Manitoba","place":["Winnipeg, Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2026,6,22]]},"reference":[{"key":"e_1_3_4_3_1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21763"},{"key":"e_1_3_4_4_1","unstructured":"National Cancer Institute. Female breast cancer subtypes - cancer stat facts [Internet]. Surveill. Epidemiol. End results SEER program. [cited 2024 Nov 5]. Available from: https:\/\/seer.cancer.gov\/statfacts\/html\/breast-subtypes.html"},{"key":"e_1_3_4_5_1","unstructured":"National Comprehensive Cancer Network. Clinical practice guidelines in oncology (NCCN guidelines\u00ae) breast cancer version 1.2025. [Internet]. 2025. Available from: https:\/\/www.nccn.org\/guidelines\/guidelines-detail?category=1&id=1419"},{"key":"e_1_3_4_6_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2016.0891"},{"key":"e_1_3_4_7_1","unstructured":"US Food and Drug Administration. FDA approves capivasertib with fulvestrant for breast cancer [Internet]. 2024 [cited 2024 Oct 21]. Available from: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-capivasertib-fulvestrant-breast-cancer"},{"key":"e_1_3_4_8_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2214131"},{"key":"e_1_3_4_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2024.03.258"},{"key":"e_1_3_4_10_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1813904"},{"key":"e_1_3_4_11_1","doi-asserted-by":"publisher","DOI":"10.51731\/cjht.2024.977"},{"key":"e_1_3_4_12_1","unstructured":"AstraZeneca. Full year and Q4 2024 results [Internet]. 2025. Available from: https:\/\/www.astrazeneca.com\/content\/dam\/az\/PDF\/2024\/fy\/Full-year-and-Q4-2024-results-announcement.pdf"},{"key":"e_1_3_4_13_1","unstructured":"Drugs.com. Truqap prices coupons copay cards & patient assistance [Internet]. 2024 [cited 2024 Oct 15]. Available from: https:\/\/www.drugs.com\/price-guide\/truqap"},{"key":"e_1_3_4_14_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40273-024-01456-x"},{"key":"e_1_3_4_15_1","unstructured":"Worldometer. U.S. population [Internet]. 2024 [cited 2024 Aug 21]. Available from: https:\/\/www.worldometers.info\/world-population\/us-population\/"},{"key":"e_1_3_4_16_1","unstructured":"Centers for Disease Control and Prevention. U.S. cancer statistics breast cancer stat bite [Internet]. U. S. Cancer Stat; 2024 [cited 2025 Mar 3]. Available from: https:\/\/www.cdc.gov\/united-states-cancer-statistics\/publications\/breast-cancer-stat-bite.html"},{"key":"e_1_3_4_17_1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21731"},{"key":"e_1_3_4_18_1","unstructured":"U.S. Census Bureau. U.S. Population as of January 1 2022 [Internet]. [cited 2024 Aug 17]. Available from: https:\/\/www.census.gov\/library\/stories\/2021\/12\/happy-new-year-2022.html"},{"key":"e_1_3_4_19_1","doi-asserted-by":"publisher","DOI":"10.1093\/jncics\/pkab063"},{"key":"e_1_3_4_20_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.62.3504"},{"key":"e_1_3_4_21_1","doi-asserted-by":"publisher","DOI":"10.3111\/13696998.2012.749788"},{"key":"e_1_3_4_22_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40261-023-01325-z"},{"key":"e_1_3_4_23_1","unstructured":"Centers for Medicare & Medicaid Services. Average sales price (ASP) pricing files [Internet]. 2023. Available from: https:\/\/www.cms.gov\/medicare\/payment\/part-b-drugs\/asp-pricing-files"},{"key":"e_1_3_4_24_1","unstructured":"Drugs.com. Exemestane prices coupons copay cards & patient assistance [Internet]. [cited 2024 Dec 27]. Available from: https:\/\/www.drugs.com\/price-guide\/exemestane"},{"key":"e_1_3_4_25_1","unstructured":"Drugs.com. Tamoxifen prices coupons copay cards & patient assistance [Internet]. [cited 2025 Feb 7]. Available from: https:\/\/www.drugs.com\/price-guide\/tamoxifen"},{"key":"e_1_3_4_26_1","unstructured":"Drugs.com. Ranitidine prices coupons copay cards & patient assistance [Internet]. [cited 2024 Dec 29]. Available from: https:\/\/www.drugs.com\/price-guide\/ranitidine"},{"key":"e_1_3_4_27_1","unstructured":"Centers for Medicare & Medicaid Services. Physician fee schedule [Internet]. 2023 [cited 2024 Aug 1]. Available from: https:\/\/www.cms.gov\/medicare\/physician-fee-schedule\/search"},{"key":"e_1_3_4_28_1","unstructured":"Centers for Medicare & Medicaid Services. Clinical laboratory fee schedule [Internet]. 2023 [cited 2024 Aug 1]. Available from: https:\/\/www.cms.gov\/medicare\/payment\/fee-schedules\/clinical-laboratory-fee-schedule-clfs"},{"key":"e_1_3_4_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clbc.2015.04.001"},{"key":"e_1_3_4_30_1","doi-asserted-by":"publisher","DOI":"10.1186\/2193-1801-3-259"},{"key":"e_1_3_4_31_1","unstructured":"Canada\u2019s Drug Agency. Pharmacoeconomic report: alpelisib (Piqray) [Internet]. 2022. Available from: https:\/\/www.cda-amc.ca\/alpelisib"},{"key":"e_1_3_4_32_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx201"},{"key":"e_1_3_4_33_1","unstructured":"Drugs.com. Piqray prices coupons copay cards & patient assistance [Internet]. [cited 2024 Oct 15]. Available from: https:\/\/www.drugs.com\/price-guide\/piqray"},{"key":"e_1_3_4_34_1","unstructured":"Drugs.com. Everolimus prices coupons copay cards & patient assistance [Internet]. [cited 2024 Aug 1]. Available from: https:\/\/www.drugs.com\/price-guide\/everolimus"},{"key":"e_1_3_4_35_1","unstructured":"U.S. Food and Drug Administration. TRUQAPTM (capivasertib) tablets for oral use [Internet]. 2023. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/218197s000lbl.pdf"},{"key":"e_1_3_4_36_1","unstructured":"U.S. Food and Drug Administration. PIQRAY\u00ae (alpelisib) tablets for oral use [Internet]. 2019. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/212526s009lbl.pdf"},{"key":"e_1_3_4_37_1","unstructured":"United Kingdom National Health Service. Side effects of hormone replacement therapy (HRT) [Internet]. 2023 [cited 2025 Jun 5]. Available from: https:\/\/www.nhs.uk\/medicines\/hormone-replacement-therapy-hrt\/side-effects-of-hormone-replacement-therapy-hrt\/"},{"key":"e_1_3_4_38_1","unstructured":"Canadian Cancer Society. Side effects of chemotherapy [Internet]. 2024 [cited 2025 Jun 5]. Available from: https:\/\/cancer.ca\/en\/treatments\/treatment-types\/chemotherapy\/side-effects-of-chemotherapy"},{"key":"e_1_3_4_39_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1524-4733.2007.00187.x"},{"key":"e_1_3_4_40_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.16_suppl.1041"},{"key":"e_1_3_4_41_1","unstructured":"National Comprehensive Cancer Network. Clinical practice guidelines in oncology (NCCN guidelines\u00ae) breast cancer version 1.2024. 2024."},{"key":"e_1_3_4_42_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.24.00248"},{"key":"e_1_3_4_43_1","unstructured":"Australian Pharmaceutical Benefits Scheme. Public summary document (Capivasertib) [Internet]. 2024. Available from: https:\/\/www.pbs.gov.au\/industry\/listing\/elements\/pbac-meetings\/psd\/2024-11\/files\/capivasertib%20PSD-november-2024-with-addendum-march-2025.pdf"},{"key":"e_1_3_4_44_1","unstructured":"United Kingdom\u2019s National Institute of Health and Care Excellence. Capivasertib with fulvestrant for treating hormone receptor-positive HER2-negative advanced breast cancer after endocrine treatment. 2025. Available from: https:\/\/www.nice.org.uk\/guidance\/ta1063\/resources\/capivasertib-with-fulvestrant-for-treating-hormone-receptorpositive-her2negative-advanced-breast-cancer-after-endocrine-treatment-pdf-2973528574413253"},{"key":"e_1_3_4_45_1","unstructured":"Canadian Breast Cancer Network. Breast cancer drug information (Capivasertib). Internet. [cited 2026 Apr 2]. Available from: https:\/\/www.cbcn.ca\/en\/listing-directory\/drug-navigation-tool\/capivasertib?utm_source=chatgpt.com"}],"container-title":["Expert Review of Pharmacoeconomics & Outcomes Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14737167.2026.2691183","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/full-xml\/10.1080\/14737167.2026.2691183","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14737167.2026.2691183","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T10:03:16Z","timestamp":1783936996000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14737167.2026.2691183"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,22]]},"references-count":43,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,7,3]]}},"alternative-id":["10.1080\/14737167.2026.2691183"],"URL":"https:\/\/doi.org\/10.1080\/14737167.2026.2691183","relation":{},"ISSN":["1473-7167","1744-8379"],"issn-type":[{"value":"1473-7167","type":"print"},{"value":"1744-8379","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,22]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ierp20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ierp20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2025-12-25","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-06-08","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-06-22","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}